“Our study found that many months after SARS-CoV-2 infection, there were still abnormal immune cells in the airways of patients with persistent breathlessness. We also identified a protein ‘signature’ in the lungs indicating ongoing injury to the airways.”

Conclusions: Our data suggest that patients with severe asthma or atopic dermatitis on biologic therapies have lower antibody levels after SARS-CoV-2 mRNA vaccination compared to healthy adults. It is unclear if these differences are due to the biologic therapies or confounding factors commonly seen in these patients. Nevertheless, as there is...

Conclusions: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.

Interpretation: We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according to vaccine type. With respect to severe COVID-19, vaccine effectiveness seemed to be better maintained, although some waning became evident after 4 months. The results...

Our results are broadly consistent with a multi-component model of Covid-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication, or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between...